Milan Lukáš
Introduction of biological therapy in patients with Crohn`s disease and ulcerative colitis is associated with the crucial changes in all therapeutical aspects in IBD. The complex care based on team cooperation is required due to therapeutical efficacy and side effects monitoring. Disease activity evaluation and disease extension before therapy starts should be done. The positive therapeutical effect was proved in 80 % patients treated by biological therapy in clinical practice. The patients who are primary non-responders are not frequent and they have been determined in 10 % of patients maximally. The theraputic efficacy in infliximab and adalimumab is similar in luminal Crohn`s disease. The unsolved problems are secondary therapeutic failure, the most suitable intensification strategy and co-therapy with immunosuppressants.